Recent Updates
Recently added Catalysts
CMPS Positive Sentiment

Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights

Key Takeaway: Compass Pathways plc has announced its financial results for the second quarter and first half of 2026. The company is focused on advancing its mental health treatment options, particularly with the COMP360 product. CEO Kabir's remarks highlight a period of significant progress in clinical, regulatory, and commercial activities.
Price reaction · baseline $11.8 (2026-08-04 close) · hit pre-market · 2 other CMPS headline(s) in the window, move may be shared
day 0 close · peak
+15.1%
day 1
+14.8%
day 3
+11.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Compass Pathways reported strong financial results for Q2 and H1 2026.
  • The company is building momentum in clinical and regulatory areas.
  • Preparation for the potential approval and launch of COMP360 is underway.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~25 mo
Minimal dilution risk
Lead asset
Psilocybin
Phase 3 · Major Depressive Disorder

Full Press Release Details

Compass Management will host a conference call at 8:00 am ET (1:00 pm UK)

LONDON & NEW YORK--(BUSINESS WIRE)--$CMPS#Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that it will release financial results for the second quarter and first half ended June 30, 2026, on August 5, 2026.
Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on August 5, 2026. A live webcast of the call will be available on the Compass Pathways website at:https://events.q4inc.com/attendee/246696001. The webcast will be archived for 30 days.

About Compass Pathways

We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. Our initial focus is developing COMP360 psilocybin, a proprietary, investigational, synthetic psilocybin treatment under evaluation for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). COMP360 is a potentially first-in-class treatment and has Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA), as well as Innovative Licensing and Access Pathway (ILAP) designation in the UK for TRD. We are leading the world’s largest classic psychedelic clinical program in TRD, and building upon that robust foundation, we are executing a late-stage trial evaluating COMP360 for PTSD, another condition with high unmet need. Our goal is to advance treatments that move the field of psychiatry towards treatment options that offer rapid onset and sustained durability with infrequent dosing.
Compass is headquartered in London, UK, with a U.S. office in New Jersey.
We are driven by our purpose of unlocking pathways to be – opening futures filled with possibility. Together, we are on an ambitious journey toward enabling people living with mental health conditions to find clarity through self-discovery, because every journey needs a Compass.

Enquiries

Media: Dana Sultan-Rothman,media@compasspathways.com
Investors: Stephen Schultz,stephen.schultz@compasspathways.com, +1 401 290 7324

Frequently Asked Questions

What financial results did Compass Pathways announce?

Compass Pathways reported its financial results for Q2 and H1 2026, showing strong performance.

What is COMP360?

COMP360 is a treatment option being developed by Compass Pathways for mental health care.

Who is the CEO of Compass Pathways?

Kabir is the CEO of Compass Pathways, emphasizing the company's progress.

What areas is Compass Pathways focusing on?

Compass Pathways is focusing on clinical, regulatory, and commercial fronts.

Last updated: Aug 5, 2026